Year Founded
2012
Ownership
Private
Employees
~50
Stage
Phase 1
Modalities
Protein therapeuticsAntibody-drug conjugate (ADC)Small interfering RNA (siRNA)RadiopharmaceuticalsAntibody-drug conjugate (ADC)

Linxis Biopharmaceuticals General Information

Developing first-in-class ADCs using proprietary platinum(II)-based Lx linker technology. Lead programs include Fibrobody-drug conjugates for fibrosis and cancer. Demonstrated favorable preclinical safety profile and superior therapeutic efficacy compared to conventional ADC approaches.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office

Drug Pipeline

Fibrobody-Tracer Conjugate
Phase 1/2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Linxis Biopharmaceuticals's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Linxis Biopharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Linxis Biopharmaceuticals's complete valuation and funding history, request access »